Oxular appoints Dr. Friedrich Asmus as Chief Medical Officer

OXFORD, England, June 7, 2021 /PRNewswire/ -- Oxular Limited, a leading retinal therapeutics development company, today announces it has appointed Dr. Friedrich (Fritz) Asmus as Chief Medical Officer. Dr. Asmus will lead all medical, clinical, and regulatory functions to further the Company's lead asset, OXU–001, for the treatment of diabetic macular edema (DME), and to accelerate the development of its early-product pipeline.

Dr. Asmus is a board-certified neurologist and pharmacist and, for more than 10 years, has successfully headed clinical development programs in the US, Europe, and Asia. Fritz was a key strategic leader in the successful development of alfibercept and other ophthalmic therapies at Bayer Pharma, including indications for DME, diabetic retinopathy, and retinal vein occlusions. Fritz also led development activities for rare ophthalmic diseases at ProQR Therapeutics and jCyte, where he headed the intravitreal oligonucleotide program for genetic forms of Retinitis pigmentosa (RP) and clinical development for an intravitreal cell therapy program for RP, respectively. Fritz holds a private lectureship for Neurology at the University Hospital of Tuebingen, Germany, where he was also Deputy Chair of the Department of General Neurology. He has published over 50 peer-reviewed articles in ophthalmology and neurology.

Prof. Marc D. de Smet, who has served as Oxular's Chief Medical Officer in a part time capacity alongside his private clinical practice, will continue working with the Company as Senior Medical Advisor, bringing his world-leading retinal expertise to the ongoing development of the Company's programs and technology.

Fritz's appointment follows Oxular's successful completion of a $37m financing in March 2021 and is a significant milestone in building the Oxular team to support future clinical trials and expanded R&D activities. Fritz joins as Oxular prepares to initiate human clinical trials for its lead asset, OXU-001, an extended-duration treatment for DME.

Thomas Cavanagh, Chief Executive Officer of Oxular, commented:

"We are pleased to have Fritz join our leadership team, especially at this critical time when we are readying OXU–001 to begin human clinical studies and accelerating further the development of our highly differentiated product pipeline. Fritz's depth of knowledge and experience in back-of-eye therapies will be highly advantageous in delivering on our pipeline's promise of effective and longer-lasting treatments that offer patients truly life-changing solutions to their unmet needs.

"I'd like to acknowledge and thank Prof. de Smet for his incredible work over the last three years. The Company would not have advanced this far without his advice and expertise, and I look forward to continuing to work with Marc as the Company's programs begin human clinical trials and as we expand use of Oxulumis™ (suprachoroidal space, illuminated microcatheter) to deliver important treatments for sight threatening diseases."

Dr. Friedrich Asmus, Chief Medical Officer of Oxular, commented:

"I have been really impressed with the work scientists at Oxular have delivered in supporting an expanded role of drug delivery to the suprachoroidal space. It is a great privilege to be part of Oxular's team, driving outstanding innovation to establish an entire product platform of suprachoroidal therapies for areas of high unmet patient need in common and ultra-rare ophthalmic indications."

Enquiries

About Oxular Limited

"One treatment a year. Life changing."

Oxular is developing disruptive technology to transform the treatment of retinal disease, offering patients life-changing solutions to their unmet needs. Oxular's sustained-release formulations are engineered to last up to one year following single administration and perform in specific small spaces in the eye. This approach provides unique and precise drug distribution to tissues specifically involved in retinal diseases. Oxular's drug administration technology is engineered to access these critical tissues through minimally invasive delivery. This novel combination aims to substantially improve patient quality of life by increasing therapeutic effectiveness and patient safety, while reducing side-effects and minimizing the frequency of treatments. Oxular's product development pipeline includes treatments for prevalent retinal diseases, such as diabetic macular edema and diabetic retinopathy, as well as rare and orphan indications, including treatments for ocular cancers.

For more information refer to www.oxular.com.

SOURCE Oxular Limited

Related Links

https://oxular.com